| 01/11/2023 |
1Q: Refocused Business Cutting Expenses, Progressing Trials
|
MST Access |
| 09 /10/2023 |
Pharmaxis evolves into Syntara: sells mannitol unit; sharpening operational focus and cutting costs
|
MST Access |
| 06/10/2023 |
Restructured to Smaller, More Agile Drug Developer
|
Morgans |
| 05/09/2023 |
Positive PXS-5505 Preclinical Data Published in Peer-Reviewed Journal
|
MST Access |
| 22/8/2023 |
Clinical-stage pipeline continues to advance
|
Morgans |
| 14/8/2023 |
Pharmaxis -Meaningful Impact on Bone Marrow in Myelofibrosis Study
|
Bioshares |
| 21/6/2023 |
Progressing to Next Stage in Scarring and Myelofibrosis
|
Taylor Collison |
| 06/06/2023 |
Mixed Results from Pharmaxis' Scar Treatment Study
|
Bioshares |
| 25/05/2023 |
Pleasing Results from Established Scars, Phase 1c – More to Come
|
MST Access |
| 05/05/2023 |
3Q: Cash Balance Comfortable as Key Trials Proceed in Tandem
|
MST Access |
| 01/05/2023 |
Pharmaxis Phase II Trial Results Approaching
|
Bioshares |
| 13/04/2023 |
Useful FDA Feedback Paves Way for New Arm of Lead Clinical Trial
|
MST Access |
| 30-03-2023 |
Raising PXS-5505 Profile in New Indication, Synergies with SOC
|
MST Access |
| 28-03-2023 |
Pharma's Market
|
Bell Potter |
| 24-02-2023 |
Pharmaxis: A Re-Rating Approaching?
|
Bioshares |
| 20-02-2023 |
2QFY23 – news flow plentiful in 2023 with data readouts from two major trials
|
MST Access |
| 27-12-2022 |
Top 6 Stock Picks for 2023: Will 2023 be the Breakout Year for Pharmaxis?
|
Bioshares |
| 09-11-2022 |
1QFY23 Release Shows Diverse Pipeline Continuing to Deliver News Flow
|
MST Access |
| 04-11-2022 |
Pharmaxis Releases Initial Data in Myelofibrosis
|
Bioshares |
| 07-10-2022 |
Encouraging initial efficacy data, adding new programs
|
Taylor Collison |
| 19-09-2022 |
Pharmaxis: Can PXS-6302 'Un-scar the
Scar'?
|
Bioshares |
| 12-09-2022 |
Pharmaxis Repurposes PXS-4728 for Parkinson's Disease
|
Bioshares |
| 02-09-2022 |
New collaboration to study PXS-4728 for early neurodegenerative treatment |
MST Access |
| 16-August-2022 |
Building up its short-term cash position |
Morgans |
| 05-08-2022 |
Pharmaxis Sells Orbital Technology for US$5 Million
|
Bioshares |
| 15-June-2022 |
Clinical trials on track; news flow ahead |
MST Access |
| 12-April-2022 |
Following the Science |
Morgans |
| 08-April-22 |
PXS-5505 and PXS-6320 R&D Days |
Taylor Collison |
| 15-Feb-22 |
Pharmaxis Update |
Bioshares |
| 31-Jan-22 |
Making tracks with concurrent trials; 2Q results announced |
MST Access |
| 6-Dec-21 |
New capital extends cash runway |
MST Access |
| 30-Nov-21 |
Initiation Report: Pharmaxis - Exploring Efficacy in Cancer and Fibrosis |
Taylor Collison |
| 24-Nov-21 |
Updated report |
Emerald |
| 12-Nov-21 |
New indication for PXS-5505 |
MST Access |
| 1-Nov-21 |
Initiation of Coverage |
MST Access |
| 18-May-21 |
Initial report |
Emerald |
| 19-Apr-21 |
Karst Peak Continues Investment in Austalia Biotech |
Bioshares |
| 15-Feb-21 |
Pharmaxis Makes First Commercial Bronchitol Shipment to USA |
Bioshares |
| 13-Feb-21 |
1H21 – Result Summary |
Bell Potter |
| 7-Jan-21 |
FDA approval for Bronchitol revamps the business, improves outlook |
Bell Potter |
| 3-Nov-20 |
Bronchitol FDA Approval a Turning Point for Pharmaxis |
Bioshares |
| 7-Sep-20 |
Boehringer Ends Development of Pharmaxis Compound |
Bioshares |
| 7-Sep-20 |
BI terminates agreement, discontinues |
Bell Potter |
| 19-Aug-20 |
FDA clears IND for myelofibrosis study |
Bell Potter |
| 13-Aug-20 |
FY20 Audited Results - No Material Change |
Bell Potter |
| 10-Aug-20 |
A Big Six Months Ahead for Pharmaxis |
Bioshares |
| 5-Aug-20 |
Key catalysts expected in Q4CY20 |
Bell Potter |
| 22-May-20 |
COVID-19 impacting timing for key catalysts |
Bell Potter |
| 4-May-20 |
Pharmaxis - Multiple Assets to Drive Value |
Bioshares |
| 24-Feb-20 |
Pharmaxis Remains Confident of Securing LOXL2 Deal |
Bioshares |
| 13-Feb-20 |
1H20 Audited Results - No Material Change |
Bell Potter |
| 6-Feb-20 |
Down but not out, with turnaround prospects strong in CY20 |
Bell Potter |
